000			03937nam a22003855i 4500
001			85899
003			ES-MaUEC
005			20230207040533.0
007			cr nn 008mamaa
008			160521s2016 gw | s |||| 0|eng d
020			_a9783319322322
040			_aES-MaUEC
050		4	_aRM301.4 _bR673 2016
082	0	4	_a631.52
082	0	4	_a660.6
100	1		_aRosales-Mendoza, Sergio. _985028 _0Local
245	1	0	_aAlgae-Based Biopharmaceuticals _cby Sergio Rosales-Mendoza
260			_aCham _bSpringer International Publishing _c2016
300			_a1 recurso en línea (X, 166 páginas) _b47 ilustraciones, 22 ilustraciones en color
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aThe Biopharmaceuticals Field and Algae as Expression Hosts -- Genetic Engineering Approaches for Algae -- Algae-made Vaccines Targeting Human Diseases -- Algae-made Vaccines Targeting Animal Pathogens -- Algae-made Antibodies and Immunotoxins -- Algae-made Cytokines and Growth Factors -- Other Biopharmaceuticals Produced in Algae -- Algae-made Nutraceuticals -- Perspectives for the Algae-made Biopharmaceuticals Field.
520	3		_aThis book constitutes a key reference on the use of algae in the BFs production field; providing an updated outlook on the achievements accomplished thus far and transmitting a prospective view for this biotechnological application. This book provides a detailed description of the technology as well as an updated outlook of the strides achieved thus far in the field of algae-based biopharmaceuticals. Algae constitute attractive expression hosts for the production of recombinant proteins with medical applications. Among the features that make them attractive candidates are: low cost, fast growth, wide biosynthetic capacity, and absence of human pathogens; which constitute substantial advantages with respect to bacterial and mammalian systems. First, the features of algae as convenient hosts for the production of BFs are analyzed in terms of production costs, biosynthetic capacity, and safety (Chapter 1). Second, the genetic engineering tools for algae-species are described. Nuclear and chloroplast-based expression approaches are analyzed and compared in terms of biosynthetic advantages, gene expression complexity, and DNA transfer approaches (Chapter 2). In the following sections, chapters 3 to 7, the state of the art on producing distinct types of BFs in algae species is presented. Although this book is mainly focused on BFs, considering that the production of compounds with health-promoting properties are achieved using genetically-engineered algae strains, chapter 8 deals with nutraceuticals. In the ninth chapter, the developments reported thus far are placed in perspective and challenges for the field are discussed. Critical future prospects comprise the following: optimizing large-scale production in bioreactors, implementing glycoengineering approaches, optimizing nuclear expression, exploring new approaches for oral delivery, and implementing regulatory frameworks to accomplish technology transfer and regulatory approval of algae-made BFs.
710	2		_aSpringerLink (Online service) _0Local _9106996
942			_2lcc _cLE
988			_aEBOOK, asignarmaterias , EBSPRINGER
650	0	4	_9495993 _aCiencias de la vida
650		7	_aTecnología farmacéutica _0comprobar BNE20030698632 _2embne _9161127
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-32232-2 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9783319322322
907			_a.b12951778 _b10-10-17 _c21-11-16
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _ggw _h0
945			_aRM301.4 R673 2016 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i1159455x _z06-04-17
999			_c85899 _d85899 _x1